Objective: One-year adjuvant trastuzumab therapy increases diseasefree and overall survival in the adjuvant treatment of early HER2positive breast cancer. This study aims to assess the long-term cost-effectiveness of adjuvant trastuzumab treatment in Beijing, Shang-
